Article originally posted on The Clinical Trial Vanguard by Moe Alsumidaie on November 3, 2025
Article originally posted on The Clinical Trial Vanguard by Moe Alsumidaie on November 3, 2025
At DPHARM, we spoke with Patrick McNamara, Chief Commercial Officer at Yunu, about how the company is transforming imaging workflows by addressing site-level pain points first—a strategy that has since captured the attention of major sponsors.
McNamara emphasized that “sites are our customers,” noting that for decades, imaging in research has been fragmented by point solutions with no connectivity. By enabling real-time data access and transparent collaboration across sites, radiologists, CROs, and sponsors, Yunu rebuilt trust and drastically improved data quality. “Before Yunu adoption, error rates at large comprehensive cancer centers ranged from 25% to 50%. After adoption, they dropped to under 2%,” he said.
Discussing audit readiness, McNamara highlighted a major cancer center that underwent a five-day FDA audit with zero findings—a result he attributes to Yunu’s fully traceable and transparent platform. With the emergence of R3 requirements emphasizing data digitization and governance, McNamara noted that imaging “has been a black box” for too long, and Yunu is changing that paradigm by giving sponsors visibility into every image across every site in real time.
He also described the growing “Yunuverse,” a connected network of imaging stakeholders that allows trial worklists to move seamlessly between institutions, eliminating backlogs and delays. McNamara underscored that access to quality imaging should not depend on geography—Yunu powers both Ivy League institutions and small community hospitals on the same platform.
Calling current imaging inefficiencies “unethical to the patient, the study, and data quality,” McNamara urged the industry to adopt technologies that eliminate avoidable disqualifications and delays. “The technology exists to prevent it,” he said.
Website | Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.
